Want to see DMRA full AI Analyst Report?
Damora Therapeutics (DMRA) Stock Statistics & Valuation Metrics
Total Valuation
Damora Therapeutics has a market cap or net worth of $1.35B. The enterprise value is $918.32M.
- Market Cap
- $1.35B
- Enterprise Value
- $918.32M
Share Statistics
Damora Therapeutics has 61,904,743 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 61,904,743
- Owned by Insiders
- 15.92%
- Owned by Institutions
- 19.68%
Financial Efficiency
Damora Therapeutics’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -87.69%.
- Return on Equity (ROE)
- -0.87
- Return on Assets (ROA)
- -0.81
- Return on Invested Capital (ROIC)
- -87.69%
- Return on Capital Employed (ROCE)
- -0.88
- Revenue Per Employee
- 0
- Profits Per Employee
- -29.98M
- Employee Count
- 7
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Damora Therapeutics is -0.19. Damora Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -0.19
- PS Ratio
- 0.00
- PB Ratio
- 0.78
- Price to FCF
- -24.74
- Price to Operating Cash Flow
- -6.56
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Damora Therapeutics had revenue of 0 and earned -209.84M in profits. Earnings per share was -152.99.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -210.87M
- Pretax Income
- -209.79M
- Net Income
- -209.84M
- EBITDA
- -209.75M
- Earnings Per Share (EPS)
- -152.99
Cash Flow
In the last 12 months, operating cash flow was -59.13M and capital expenditures 0, giving a free cash flow of -59.13M billion.
- Operating Cash Flow
- -59.13M
- Free Cash Flow
- -59.13M
- Free Cash Flow per Share
- -3.61
Dividends & Yields
Damora Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.06%
- Earnings Yield
- -75.62%
Stock Price Statistics
- Beta
- 0.00
- 52-Week Price Change
- 307.22%
- 50-Day Moving Average
- 23.02
- 200-Day Moving Average
- 25.63
- Relative Strength Index (RSI)
- 60.18
- Average Volume (3m)
- 535.25K
Important Dates
Damora Therapeutics upcoming earnings date is Mar 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Damora Therapeutics as a current ratio of 12.98, with Debt / Equity ratio of 0.03%
- Current Ratio
- 12.98
- Quick Ratio
- 12.98
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.23
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Damora Therapeutics has paid 50.00K in taxes.
- Income Tax
- 50.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Damora Therapeutics EV to EBITDA ratio is -3.69, with an EV/FCF ratio of -18.71.
- EV to Sales
- 0.00
- EV to EBITDA
- -3.69
- EV to Free Cash Flow
- -18.71
- EV to Operating Cash Flow
- -18.71
Balance Sheet
Damora Therapeutics has $528.48M in cash and marketable securities with $1.10M in debt, giving a net cash position of $527.38M billion.
- Cash & Marketable Securities
- $528.48M
- Total Debt
- $1.10M
- Net Cash
- $527.38M
- Net Cash Per Share
- $8.52
- Tangible Book Value Per Share
- $30.29
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Damora Therapeutics is $47.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $47.14
- Price Target Upside
- 98.92% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 8
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -916.03%
Scores
- Smart Score
- 9
- AI Score
- 47
